No Data
No Data
Fosun Pharma Announces New Drug Acceptance
NMPA Accepts Shanghai Fosun Pharmaceutical's Drug Registration Application
Fosun Pharma (600196.SH): Its holding subsidiary's application for pharmaceutical registration has been accepted.
On July 22, GLH, Fosun Pharma (600196.SH) announced that its subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. received a notification from the National Medical Products Administration that the following pharmaceutical registration applications have been accepted: 1. Nitroprusside Sodium Injection (referred to as "New Drug 1"), intended for: (1) emergency blood pressure reduction for hypertensive emergencies such as hypertensive crises, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension before and after surgery for pheochromocytoma, and can also be used for controlled hypotension during surgical anesthesia; (2) acute heart failure, including acute pulmonary edema, and also for acute myocardial infarction or valve (mitral
Shanghai Fosun Pharmaceutical Unit Gets China Nod for Poison Antidote
Fosun Pharma (600196.SH, 02196) deepens its CNS layout and the cooperative product, the global first 128-channel liquid-helium-free magnetoencephalogram, has been approved for marketing.
Innovative medical instrument products developed independently by Beijing Micromed Technology, a strategic partner of Fosun Medical Instruments, have been officially approved for listing, including the no-liquid-helium magnetoencephalography system (MEG).
Fosun Pharma's New Drug Application Accepted
No Data